{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T07:35:57Z","timestamp":1775374557869,"version":"3.50.1"},"reference-count":67,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The ultra-short-acting benzodiazepine remimazolam, approved for procedural sedation\nand general anesthesia, is inactivated by carboxylesterase 1 (CES1).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>Remimazolam\u00b4s involvement in CES1-mediated drug-drug interactions (DDIs) was investigated.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Possible interactions of remimazolam were studied in co-exposure experiments with eleven different\ndrugs. Further, substrates and inhibitors of CES1, identified in the literature, were evaluated for possible\nin-vivo inhibition using pharmacokinetic and Ki or IC50 values. Compounds with only one published inhibitory\nconcentration and CES1 substrates lacking inhibition data were assigned conservative Ki values.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>In human liver homogenates and\/or blood cells, remimazolam showed no significant inhibition of\nesmolol and landiolol metabolism, which, in turn, at up to 98 and 169 \u03bcM, respectively, did not inhibit remimazolam\nhydrolysis by human liver homogenates. In human liver S9 fractions, IC50 values ranged from 0.69\n\u03bcM (simvastatin) and 57 \u03bcM (diltiazem) to &gt; 100 \u03bcM (atorvastatin) and, for the remaining test items (bupropion,\ncarvedilol, nelfinavir, nitrendipine, and telmisartan), they ranged from 126 to 658 \u03bcM. Remifentanil\nwas ineffective even at 1250 \u03bcM. Guidance-conforming evaluation revealed no relevant drug-drug interactions\nwith remimazolam via CES1. The algorithm-based predictions were consistent with human study data.\nAmong CES1 inhibitors and substrates identified in the literature, only dapsone and rufinamide were found to\nbe possible in-vivo inhibitors of remimazolam metabolism.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Data and analyses suggest a very low potential of remimazolam for pharmacokinetic DDIs mediated\nby CES1. The theoretical approach and compiled data are not specific to remimazolam and, hence,\napplicable in the evaluation of other CES1 substrates.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113892002308233240801104910","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T06:38:38Z","timestamp":1723012718000},"page":"431-445","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Carboxylesterase 1-Based Drug-Drug Interaction Potential of Remimazolam: In-Vitro Studies and Literature Review"],"prefix":"10.2174","volume":"25","author":[{"given":"Karl-Uwe","family":"Petersen","sequence":"first","affiliation":[{"name":"Department of Pharmacology, RWTH Aachen University, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Schmalix","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Schmalix Pharma\nConsult, Gr\u00f6benzell, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Pesic","sequence":"additional","affiliation":[{"name":"Department of R &amp; D, Paion Germany GmbH, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7162-5786","authenticated-orcid":true,"given":"Thomas","family":"Stohr","sequence":"additional","affiliation":[{"name":"Department of R &amp; D, Paion Germany GmbH, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.chest.2018.09.015","volume":"155","author":"Pastis N.J.","year":"2019","unstructured":"Pastis N.J.; Yarmus L.B.; Schippers F.; Ostroff R.; Chen A.; Akulian J.; Wahidi M.; Shojaee S.; Tanner N.T.; Callahan S.P.; Feldman G.; Lorch D.G.; Ndukwu I.; Pritchett M.A.; Silvestri G.A.; Safety and efficacy of remimazolam compared with placebo and midazolam for moderate sedation during bronchoscopy. Chest  2019,155(1),137-146","journal-title":"Chest"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.gie.2018.04.2351","volume":"88","author":"Rex D.K.","year":"2018","unstructured":"Rex D.K.; Bhandari R.; Desta T.; DeMicco M.P.; Schaeffer C.; Etzkorn K.; Barish C.F.; Pruitt R.; Cash B.D.; Quirk D.; Tiongco F.; Sullivan S.; Bernstein D.; A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest Endosc  2018,88(3),427-437.e6","journal-title":"Gastrointest Endosc"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/phar.1806","volume":"36","author":"Wesolowski A.M.","year":"2016","unstructured":"Wesolowski A.M.; Zaccagnino M.P.; Malapero R.J.; Kaye A.D.; Urman R.D.; Remimazolam: Pharmacologic considerations and clinical role in anesthesiology. Pharmacotherapy  2016,36(9),1021-1027","journal-title":"Pharmacotherapy"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2174\/0113892002301026240318060307","volume":"25","author":"Schmalix W.","year":"2024","unstructured":"Schmalix W.; Petersen K.-U.; Pesic M.; St\u00f6hr T.; The metabolism of the new benzodiazepine remimazolam. Curr Drug Metab  2024,25(2),164-173","journal-title":"Curr Drug Metab"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/molecules13020412","volume":"13","author":"Hosokawa M.","year":"2008","unstructured":"Hosokawa M.; Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules  2008,13,412-431","journal-title":"Molecules"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.abb.2012.04.010","volume":"522","author":"Ross M.K.","year":"2012","unstructured":"Ross M.K.; Borazjani A.; Wang R.; Allen Crow J.; Xie S.; Examination of the carboxylesterase phenotype in human liver. Arch Biochem Biophys  2012,522(1),44-56","journal-title":"Arch Biochem Biophys"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/phar.1194","volume":"33","author":"Laizure S.C.","year":"2013","unstructured":"Laizure S.C.; Herring V.; Hu Z.; Witbrodt K.; Parker R.B.; The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy  2013,33(2),210-222","journal-title":"Pharmacotherapy"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.apsb.2018.05.005","volume":"8","author":"Wang D.","year":"2018","unstructured":"Wang D.; Zou L.; Jin Q.; Hou J.; Ge G.; Yang L.; Human carboxylesterases: A comprehensive review. Acta Pharm Sin B  2018,8(5),699-712","journal-title":"Acta Pharm Sin B"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/1389200219666180821094502","volume":"20","author":"Di L.","year":"2019","unstructured":"Di L.; The impact of carboxylesterases in drug metabolism and pharmacokinetics. Curr Drug Metab  2019,20(2),91-102","journal-title":"Curr Drug Metab"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"Page M.J.","year":"2021","unstructured":"Page M.J.; McKenzie J.E.; Bossuyt P.M.; Boutron I.; Hoffmann T.C.; Mulrow C.D.; Shamseer L.; Tetzlaff J.M.; Akl E.A.; Brennan S.E.; Chou R.; Glanville J.; Grimshaw J.M.; Hr\u00f3bjartsson A.; Lalu M.M.; Li T.; Loder E.W.; Mayo-Wilson E.; McDonald S.; McGuinness L.A.; Stewart L.A.; Thomas J.; Tricco A.C.; Welch V.A.; Whiting P.; Moher D.; The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ  2021,372(71),n71","journal-title":"BMJ"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1124\/jpet.104.081265","volume":"313","author":"Quinney S.K.","year":"2005","unstructured":"Quinney S.K.; Sanghani S.P.; Davis W.I.; Hurley T.D.; Sun Z.; Murry D.J.; Bosron W.F.; Hydrolysis of capecitabine to 5\u2032-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. J Pharmacol Exp Ther  2005,313(3),1011-1016","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=12","year":"2013","unstructured":"Sanofi-Aventis  Available from:  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020623s010lbl.pdf,020624s023lbl.pdf (accessed on 28-6-2024)2013"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1124\/dmd.110.034454","volume":"38","author":"Fukami T.","year":"2010","unstructured":"Fukami T.; Takahashi S.; Nakagawa N.; Maruichi T.; Nakajima M.; Yokoi T.; In-vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. Drug Metab Dispos  2010,38(12),2173-2178","journal-title":"Drug Metab Dispos"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1124\/dmd.106.009704","volume":"34","author":"Polsky-Fisher S.L.","year":"2006","unstructured":"Polsky-Fisher S.L.; Cao H.; Lu P.; Gibson C.R.; Effect of cytochromes P450 chemical inhibitors and monoclonal antibodies on human liver microsomal esterase activity. Drug Metab Dispos  2006,34(8),1361-1366","journal-title":"Drug Metab Dispos"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1007\/s11095-011-0637-9","volume":"29","author":"Rhoades J.A.","year":"2012","unstructured":"Rhoades J.A.; Peterson Y.K.; Zhu H.J.; Appel D.I.; Peloquin C.A.; Markowitz J.S.; Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions. Pharm Res  2012,29(4),972-982","journal-title":"Pharm Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","volume":"22","author":"Cheng C.","year":"1973","unstructured":"Cheng C.; Prusoff W.H.; Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol  1973,22(23),3099-3108","journal-title":"Biochem Pharmacol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1124\/dmd.115.066597","volume":"43","author":"Haupt L.J.","year":"2015","unstructured":"Haupt L.J.; Kazmi F.; Ogilvie B.W.; Buckley D.B.; Smith B.D.; Leatherman S.; Paris B.; Parkinson O.; Parkinson A.; The Reliability of estimating Ki values for direct, reversible inhibition of cytochrome P450 enzymes from corresponding IC50 values: a retrospective analysis of 343 experiments. Drug Metab Dispos  2015,43(11),1744-1750","journal-title":"Drug Metab Dispos"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.tox.2010.01.009","volume":"270","author":"Zhu H.J.","year":"2010","unstructured":"Zhu H.J.; Appel D.I.; Peterson Y.K.; Wang Z.; Markowitz J.S.; Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: Potential sources of metabolic drug interactions. Toxicology  2010,270(2-3),59-65","journal-title":"Toxicology"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.ajhg.2008.04.015","volume":"82","author":"Zhu H.J.","year":"2008","unstructured":"Zhu H.J.; Patrick K.S.; Yuan H.J.; Wang J.S.; Donovan J.L.; DeVane C.L.; Malcolm R.; Johnson J.A.; Youngblood G.L.; Sweet D.H.; Langaee T.Y.; Markowitz J.S.; Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet  2008,82(6),1241-1248","journal-title":"Am J Hum Genet"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1124\/dmd.114.056994","volume":"42","author":"Shimizu M.","year":"2014","unstructured":"Shimizu M.; Fukami T.; Nakajima M.; Yokoi T.; Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase. Drug Metab Dispos  2014,42(7),1103-1109","journal-title":"Drug Metab Dispos"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1124\/dmd.108.024331","volume":"37","author":"Takahashi S.","year":"2009","unstructured":"Takahashi S.; Katoh M.; Saitoh T.; Nakajima M.; Yokoi T.; Different inhibitory effects in rat and human carboxylesterases. Drug Metab Dispos  2009,37(5),956-961","journal-title":"Drug Metab Dispos"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2133\/dmpk.DMPK-12-RG-143","volume":"28","author":"Yanjiao X.","year":"2013","unstructured":"Yanjiao X.; Chengliang Z.; Xiping L.; Tao W.; Xiuhua R.; Dong L.; Evaluation of the inhibitory effects of antihypertensive drugs on human carboxylesterase in vitro. Drug Metab Pharmacokinet  2013,28(6),468-474","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/clpt.2014.183","volume":"96","author":"Kristensen K.E.","year":"2014","unstructured":"Kristensen K.E.; Zhu H-J.; Wang X.; Gislason G.H.; Torp-Pedersen C.; Rasmussen H.B.; Markowitz J.S.; Hansen P.R.; Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: A proof-of-concept study. Clin Pharmacol Ther  2014,96(6),713-722","journal-title":"Clin Pharmacol Ther"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1124\/dmd.113.053512","volume":"42","author":"Thomsen R.","year":"2014","unstructured":"Thomsen R.; Rasmussen H.B.; Linnet K.; In-vitro drug metabolism by human carboxylesterase 1: Focus on angiotensin-converting enzyme inhibitors. Drug Metab Dispos  2014,42(1),126-133","journal-title":"Drug Metab Dispos"},{"key":"ref=25","author":"Tarkiainen K.","year":"2017","unstructured":"Tarkiainen K.;  Pharmacogenetics of carboxylesterase 1  Available from:  https:\/\/helda.helsinki.fi\/bitstream\/handle\/10138\/187775\/pharmaco.pdf?sequence=1 (accessed on 28-6-20242017","journal-title":"Pharmacogenetics of carboxylesterase 1"},{"key":"ref=26","author":"Kanefendt F.","unstructured":"Kanefendt F.; Brase C.; Jungmann N.; Fricke R.; Engelen A.; Schmitz S.; Pharmacokinetics of asundexian with combined CYP3A and P-gp inhibitors and an inducer: Target in vitro and in vivo studies. Br J Clin Pharmacol 2023 Epub ahead of print","journal-title":"Br J Clin Pharmacol 2023 Epub ahead of print"},{"key":"ref=27","author":"Katzung B.G.","year":"2009","unstructured":"Katzung B.G.; Masters S.B.; Trevor A.J.;  Basic and Clinical Pharmacology  2009","journal-title":"Basic and Clinical Pharmacology"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cpdd.608","volume":"8","author":"Tanguay M.","year":"2019","unstructured":"Tanguay M.; Girard J.; Scarsi C.; Mautone G.; Larouche R.; Pharmacokinetics and comparative bioavailability of a levothyroxine sodium oral solution and soft capsule. Clin Pharmacol Drug Dev  2019,8(4),521-528","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=29","first-page":"40","volume":"9","author":"Colucci P.","year":"2013","unstructured":"Colucci P.; Yue C.S.; Ducharme M.; Benvenga S.; A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur Endocrinol  2013,9(1),40-47","journal-title":"Eur Endocrinol"},{"key":"ref=30","author":"Preston C.L.","year":"2016","unstructured":"Preston C.L.;  Ed; Stockley\u2019s Drug Interactions  2016","journal-title":"Ed; Stockley\u2019s Drug Interactions"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1124\/dmd.107.020248","volume":"36","author":"Williams E.T.","year":"2008","unstructured":"Williams E.T.; Jones K.O.; Ponsler G.D.; Lowery S.M.; Perkins E.J.; Wrighton S.A.; Ruterbories K.J.; Kazui M.; Farid N.A.; The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos  2008,36(7),1227-1232","journal-title":"Drug Metab Dispos"},{"key":"ref=32","year":"2009","unstructured":"EMA Assessment Report for Efient  Available from:  http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/000984\/WC500021975.pdf (accessed on 13-6-2024)2009","journal-title":"EMA Assessment Report for Efient"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"365110097","DOI":"10.1016\/j.cbi.2022.110097","author":"Zhang Q.","year":"2022","unstructured":"Zhang Q.; Melchert P.W.; Markowitz J.S.; In-vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir. Chem Biol Interact  2022,365110097","journal-title":"Chem Biol Interact"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"345109566","DOI":"10.1016\/j.cbi.2021.109566","author":"Song Y.Q.","year":"2021","unstructured":"Song Y.Q.; Jin Q.; Wang D.D.; Hou J.; Zou L.W.; Ge G.B.; Carboxylesterase inhibitors from clinically available medicines and their impact on drug metabolism. Chem Biol Interact  2021,345109566","journal-title":"Chem Biol Interact"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1124\/dmd.113.053595","volume":"41","author":"Ishizuka T.","year":"2013","unstructured":"Ishizuka T.; Yoshigae Y.; Murayama N.; Izumi T.; Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: Carboxymethylenebutenolidase and carboxylesterase 1. Drug Metab Dispos  2013,41(11),1888-1895","journal-title":"Drug Metab Dispos"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1177\/0091270007299763","volume":"47","author":"Derendorf H.","year":"2007","unstructured":"Derendorf H.; Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide. J Clin Pharmacol  2007,47(6),782-789","journal-title":"J Clin Pharmacol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1124\/dmd.30.12.1497","volume":"30","author":"Austin R.P.","year":"2002","unstructured":"Austin R.P.; Barton P.; Cockroft S.L.; Wenlock M.C.; Riley R.J.; The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos  2002,30(12),1497-1503","journal-title":"Drug Metab Dispos"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1124\/dmd.105.007658","volume":"34","author":"Hallifax D.","year":"2006","unstructured":"Hallifax D.; Houston J.B.; Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos  2006,34(4),724-726","journal-title":"Drug Metab Dispos"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1124\/dmd.107.018713","volume":"36","author":"Gertz M.","year":"2008","unstructured":"Gertz M.; Kilford P.J.; Houston J.B.; Galetin A.; Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. Drug Metab Dispos  2008,36(3),535-542","journal-title":"Drug Metab Dispos"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ejps.2018.08.008","volume":"123","author":"Bowman C.M.","year":"2018","unstructured":"Bowman C.M.; Benet L.Z.; An examination of protein binding and protein-facilitated uptake relating to in vitro-in vivo extrapolation. Eur J Pharm Sci  2018,123,502-514","journal-title":"Eur J Pharm Sci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2174\/187231211798472511","volume":"5","author":"Williams E.T.","year":"2011","unstructured":"Williams E.T.; Carlson J.E.; Lai W.G.; Wong Y.N.; Yoshimura T.; Critchley D.J.; Narurkar M.; Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett  2011,5(4),280-289","journal-title":"Drug Metab Lett"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.3390\/molecules24152747","volume":"24","author":"Briand E.","year":"2019","unstructured":"Briand E.; Thomsen R.; Linnet K.; Rasmussen H.B.; Brunak S.; Taboureau O.; Combined ensemble docking and machine learning in identification of therapeutic agents with potential inhibitory effect on human CES1. Molecules  2019,24(15),2747","journal-title":"Molecules"},{"key":"ref=43","unstructured":"FDA. Guidance for Industry. 2020. Available from:  https:\/\/www.fda.gov\/media\/134582\/download (accessed on 28-6-2024)"},{"key":"ref=44","year":"2020","unstructured":"PMDA Guideline on drug interaction for drug development and appropriate provision of information  Available from:  https:\/\/www.pref.hiroshima.lg.jp\/uploaded\/attachment\/342918.pdf (accessed on 13-6-2024)2020","journal-title":"PMDA Guideline on drug interaction for drug development and appropriate provision of information"},{"key":"ref=45","year":"2002","unstructured":"EMA Note for Guidance on the investigation of bioavailability and bioequivalence  Available from:  https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/note-guidance-investigation-bioavailability-and-bioequivalence_en.pdf (accessed on 28-6-2024)2002","journal-title":"EMA Note for Guidance on the investigation of bioavailability and bioequivalence"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S0277-0326(96)80009-2","volume":"15","author":"Dershwitz M.","year":"1996","unstructured":"Dershwitz M.; Rosow C.E.; Remifentanil: A truly-short-acting opioid. Semin Anesth  1996,15(1),88-96","journal-title":"Semin Anesth"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40265-013-0077-4","volume":"73","author":"Plosker G.L.","year":"2013","unstructured":"Plosker G.L.; Landiolol: A review of its use in intraoperative and postoperative tachyarrhythmias. Drugs  2013,73(9),959-977","journal-title":"Drugs"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1248\/bpb.b22-00468","volume":"45","author":"Imai T.","year":"2022","unstructured":"Imai T.; Isozaki M.; Ohura K.; Esterases involved in the rapid bioconversion of esmolol after intravenous injection in humans. Biol Pharm Bull  2022,45(10),1544-1552","journal-title":"Biol Pharm Bull"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1124\/dmd.118.086074","volume":"47","author":"Qian Y.","year":"2019","unstructured":"Qian Y.; Wang X.; Markowitz J.S.; In-vitro inhibition of carboxylesterase 1 by major cannabinoids and selected metabolites. Drug Metab Dispos  2019,47(5),465-472","journal-title":"Drug Metab Dispos"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1124\/dmd.111.043208","volume":"40","author":"Sato Y.","year":"2012","unstructured":"Sato Y.; Miyashita A.; Iwatsubo T.; Usui T.; Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver. Drug Metab Dispos  2012,40(5),902-906","journal-title":"Drug Metab Dispos"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/jat\/27.3.142","volume":"27","author":"Bailey D.N.","year":"2003","unstructured":"Bailey D.N.; Briggs J.R.; Procainamide and quinidine inhibition of the human hepatic degradation of meperidine in vitro. J Anal Toxicol  2003,27(3),142-144","journal-title":"J Anal Toxicol"},{"key":"ref=52","year":"2024","unstructured":"EMA Byfavo\u00ae Summary of Product Characteristics     https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/byfavo-epar-product-information_en.pdf2024","journal-title":"EMA Byfavo\u00ae Summary of Product Characteristics"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00540-010-0889-2","volume":"24","author":"Shiotsuka J.","year":"2010","unstructured":"Shiotsuka J.; Sanui M.; Lefor A.; Safe use of landiolol hydrochloride in a patient with marked pseudocholinesterase deficiency. J Anesth  2010,24(2),309-310","journal-title":"J Anesth"},{"key":"ref=54","year":"2013","unstructured":"EMA Guideline on the Investigation of Drug Interactions  Available from:  https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions_en.pdf (accessed on 28-6-2024)2013","journal-title":"EMA Guideline on the Investigation of Drug Interactions"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1124\/jpet.106.111807","volume":"319","author":"Shi D.","year":"2006","unstructured":"Shi D.; Yang J.; Yang D.; LeCluyse E.L.; Black C.; You L.; Akhlaghi F.; Yan B.; Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther  2006,319(3),1477-1484","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jmb.2005.07.016","volume":"352","author":"Fleming C.D.","year":"2005","unstructured":"Fleming C.D.; Bencharit S.; Edwards C.C.; Hyatt J.L.; Tsurkan L.; Bai F.; Fraga C.; Morton C.L.; Howard-Williams E.L.; Potter P.M.; Redinbo M.R.; Structural insights into drug processing by human carboxylesterase 1: Tamoxifen, mevastatin, and inhibition by benzil. J Mol Biol  2005,352(1),165-177","journal-title":"J Mol Biol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2165\/00003088-199325010-00003","volume":"25","author":"Shionoiri H.","year":"1993","unstructured":"Shionoiri H.; Pharmacokinetic drug interactions with ACE inhibitors. Clin Pharmacokinet  1993,25(1),20-58","journal-title":"Clin Pharmacokinet"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1124\/dmd.113.054353","volume":"42","author":"Laizure S.C.","year":"2014","unstructured":"Laizure S.C.; Parker R.B.; Herring V.L.; Hu Z.Y.; Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis. Drug Metab Dispos  2014,42(2),201-206","journal-title":"Drug Metab Dispos"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.1503\/cmaj.160303","volume":"189","author":"Antoniou T.","year":"2017","unstructured":"Antoniou T.; Macdonald E.M.; Yao Z.; Hollands S.; Gomes T.; Tadrous M.; Mamdani M.M.; Juurlink D.N.; Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. CMAJ  2017,189(1),E4-E10","journal-title":"CMAJ"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.7754\/Clin.Lab.2016.160142","volume":"62","author":"Yang S.","year":"2016","unstructured":"Yang S.; Cui C.; Zhang J.; Qiao R.; Angiotensin-converting enzyme\ninhibitors\u2019 influence on antiplatelet therapy of clopidogrel in\nACS. Clin. Lab.,   2016,62(10\/2016),1911-1918"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/bcp.12682","volume":"80","author":"Cressman A.M.","year":"2015","unstructured":"Cressman A.M.; Macdonald E.M.; Fernandes K.A.; Gomes T.; Paterson J.M.; Mamdani M.M.; Juurlink D.N.; A population\u2010based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors. Br J Clin Pharmacol  2015,80(4),662-669","journal-title":"Br J Clin Pharmacol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1248\/bpb.b14-00679","volume":"38","author":"Wang X.","year":"2015","unstructured":"Wang X.; Zhu H.J.; Markowitz J.S.; Carboxylesterase 1-mediated drug-drug interactions between clopidogrel and simvastatin. Biol Pharm Bull  2015,38(2),292-297","journal-title":"Biol Pharm Bull"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/bcp.12416","volume":"78","author":"Siepmann T.","year":"2014","unstructured":"Siepmann T.; Heinke D.; Kepplinger J.; Barlinn K.; Gehrisch S.; Gr\u00e4hlert X.; Schwanebeck U.; Reichmann H.; Puetz V.; Bodechtel U.; Gahn G.; Interaction of clopidogrel and statins in secondary prevention after cerebral ischaemia \u2013 A randomized, double\u2010blind, double\u2010dummy crossover study. Br J Clin Pharmacol  2014,78(5),1058-1066","journal-title":"Br J Clin Pharmacol"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1590\/S0066-782X2010005000106","volume":"95","author":"Serrano J\u00fanior C.V.","year":"2010","unstructured":"Serrano J\u00fanior C.V.; Soeiro, Ade.M.; Ara\u00fajo, L.F.; Jabot, B.; Rached, F.; Orii, N.M.; Nicolau, J.C.; Duarte, A.J.; Ramires, J.A. Lack of clopidogrel-statin interaction in patients undergoing coronary stent implantation. Arq Bras Cardiol  2010,95(3),321-327","journal-title":"Arq Bras Cardiol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jacc.2007.01.097","volume":"50","author":"Saw J.","year":"2007","unstructured":"Saw J.; Brennan D.M.; Steinhubl S.R.; Bhatt D.L.; Mak K.H.; Fox K.; Topol E.J.; Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol  2007,50(4),291-295","journal-title":"J Am Coll Cardiol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1124\/dmd.115.069096","volume":"44","author":"Bohnert T.","year":"2016","unstructured":"Bohnert T.; Patel A.; Templeton I.; Chen Y.; Lu C.; Lai G.; Leung L.; Tse S.; Einolf H.J.; Wang Y.H.; Sinz M.; Stearns R.; Walsky R.; Geng W.; Sudsakorn S.; Moore D.; He L.; Wahlstrom J.; Keirns J.; Narayanan R.; Lang D.; Yang X.; Evaluation of a new molecular entity as a victim of metabolic drug-drug interactions-An industry perspective. Drug Metab Dispos  2016,44(8),1399-1423","journal-title":"Drug Metab Dispos"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2165\/00003088-198611040-00003","volume":"11","author":"Zuidema J.","year":"1986","unstructured":"Zuidema J.; Hilbers-Modderman E.S.M.; Merkus F.W.H.M.; Clinical pharmacokinetics of dapsone. Clin Pharmacokinet  1986,11(4),299-315","journal-title":"Clin Pharmacokinet"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892002308233240801104910","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/232696\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892002308233240801104910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T13:06:41Z","timestamp":1732799201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/232696\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892002308233240801104910","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}